Key result
Platelet factor 4 carboxy-terminal peptides inhibit murine megakaryocytopoiesis, an effect neutralized by heparin.
Why the study?
The inhibitory effect of platelet factor 4 and its carboxy-terminal peptides on murine megakaryocytopoiesis and the role of heparin in neutralizing this activity were not fully characterized.
The inhibitory activity of PF4 on megakaryocytopoiesis is localized to a short carboxy-terminal region (13-24) that likely includes its heparin-binding domain.
Answers are grounded in this paper and cite their sources.
May modulate megakaryocytopoiesis via heparin-binding domains in murine models; leaves open human translation and clinical relevance.
Negative regulation of megakaryocytopoiesis is a complex process involving various cytokines. One of these cytokines is platelet factor 4 (PF4), a megakaryocyte/platelet specific protein. PF4 and a carboxy-terminal peptide related to PF4 have been reported to inhibit human and murine megakaryocytopoiesis. The growth of several megakaryoblastic cell lines: human erythroleukaemia cell line (HEL). Meg-01 and Dami, was also inhibited by PF4 and a 13-24 carboxy-terminal peptide related to PF4. We report that peptides corresponding to the 1-24 and 13-24 but not 1-13 carboxy-terminal region of PF4 inhibit murine megakaryocytopoiesis both in vivo (5 micrograms/inj) and in vitro (2.5 and 5 micrograms/ml). Moreover, such an inhibitory activity of PF4-related peptides is abrogated by heparin (5 IU/dish). These overall data indicate that carboxy-terminal PF4-related peptides retain the inhibitory effect of PF4 on both murine single MK and CFU-MK in vivo and in vitro by acting on an early stage of megakaryocytopoiesis and strongly suggest that the inhibitory activity of the multi-functional PF4 might be localized in a short carboxy-terminal region which might include, in part, the PF4 heparin binding domain.
No takes yet. Share an insight, caveat, or question.
Lebeurier et al. (1996) studied Murine megakaryocytopoiesis. Carboxy-terminal peptides (C1-24 and C13-24) of platelet factor 4 vs. C1-13 peptide was evaluated on Inhibition of murine megakaryocytopoiesis. Carboxy-terminal peptides (C1-24 and C13-24) of platelet factor 4 inhibit murine megakaryocytopoiesis in vivo and in vitro, an effect that is neutralized by heparin.
Synapse has enriched 10 related papers. Consider them for comparative context: